Clinical Trial

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Study acronym: CALIBRATE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2023-01-09; most recent amendment 2026-06-09.
Status change: Recruiting → Active, Not Recruiting 2025-03-11
Trial Details
NCT Number NCT05680818
Lead Sponsor Calcilytix Therapeutics, Inc., a BridgeBio company
Conditions Autosomal Dominant Hypocalcemia (ADH)
Enrollment 67 participants
Start Date 2023-01-06
Primary Completion 2025-08-22 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-29